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Abstract
Background: Survival after diagnosis is a fundamental concern in cancer epidemiology. In resource-rich settings,
ambient clinical databases, municipal data and cancer registries make survival estimation in real-world populations
relatively straightforward. In resource-poor settings, given the deficiencies in a variety of health-related data systems, it
is less clear how well we can determine cancer survival from ambient data.
Methods: We addressed this issue in sub-Saharan Africa for Kaposi’s sarcoma (KS), a cancer for which incidence has
exploded with the HIV epidemic but for which survival in the region may be changing with the recent advent of
antiretroviral therapy (ART). From 33 primary care HIV Clinics in Kenya, Uganda, Malawi, Nigeria and Cameroon
participating in the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortia in 2009–2012, we
identified 1328 adults with newly diagnosed KS. Patients were evaluated from KS diagnosis until death, transfer to
another facility or database closure.
Results: Nominally, 22 % of patients were estimated to be dead by 2 years, but this estimate was clouded by
45 % cumulative lost to follow-up with unknown vital status by 2 years. After adjustment for site and CD4 count,
age <30 years and male sex were independently associated with becoming lost.
Conclusions: In this community-based sample of patients diagnosed with KS in sub-Saharan Africa, almost half
became lost to follow-up by 2 years. This precluded accurate estimation of survival. Until we either generally
strengthen data systems or implement cancer-specific enhancements (e.g., tracking of the lost) in the region,
insights from cancer epidemiology will be limited.
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Survival after diagnosis is one of the most fundamental
parameters in cancer epidemiology. Survival encompasses
both the natural biologic history of a malignancy as well
as the effects of therapeutic interventions. Monitoring sur-
vival over time, for example, can be a powerful tool to
measure the cumulative impact of medical advancements.
In resource-rich settings, ambient clinical systems diag-
nose cancers as they occur in the community, municipal
registries record all deaths, and well-established cancer
registries and epidemiologic platforms (such as the Sur-
veillance, Epidemiology and End Results (SEER) program
in the U.S. [1]) combine and synthesize data to make can-
cer survival estimation in real-world populations accurate
and straightforward. In resource-poor settings, the im-
portance of cancer has recently drawn attention [2–4],
but, given the deficiencies in healthcare information sys-
tems in these regions, it is less clear how well we can de-
termine cancer survival with ambient data.
Kaposi’s sarcoma (KS) in sub-Saharan Africa is an
example of a malignancy in a resource-limited setting
which would benefit from knowledge about current
survival. KS was among the more common cancers in
Africa even before HIV [5, 6], exploded in incidence in
the HIV era [7–9], and exhibited poor survival early on
in the HIV epidemic [8, 10]. More recently, antiretroviral
therapy (ART) has substantially improved KS survival in
resource-replete settings [11–13] and is now becoming
more widely available in resource-poor settings [14].
However, the finding of improved survival in the ART
era in resource-rich settings, such as the U.S., cannot
automatically be extrapolated to resource-poor settings,
such as Africa. Important differences in availability of
oncologic care [15], co-morbidities [16], as well as differ-
ences in human host and viral etiologic pathogen [17]
suggest that we must examine KS survival directly in sub-
Saharan Africa [18–21] if we hope to understand the im-
pact of the ART era.
To address whether ambient data can answer a funda-
mental question of cancer survival in sub-Saharan Africa,
we examined the feasibility of estimating survival after a
KS diagnosis in the current era of burgeoning ART use.
We took advantage of an epidemiologic network of
clinical data from throughout sub Saharan Africa [22]
to identify a large community-representative sample of
KS cases in five countries. We then combined these
clinical data with all other available administrative data
to attempt to estimate survival after KS diagnosis.
Methods
Design and study population
Among HIV-infected adults diagnosed with KS, we per-
formed a cohort analysis of time to death using ambi-
ent clinical and administrative data. We retrospectivelyidentified a consecutive sample of HIV-infected adults
(≥18 years old) diagnosed with KS from January 2009
to July 2012 who were receiving their primary care at
one of thirty-three HIV clinics in Kenya, Uganda, Malawi,
Nigeria and Cameroon. The sites included 26 clinics in a
network in western Kenya (Academic Model Providing
Access to Healthcare (AMPATH)), one clinic in Uganda
(Immune Suppression Syndrome Clinic (ISS) in Mbarara),
two clinics in Nigeria (University of Abuja Teaching
Hospital and National Hospital of Abuja), three clinics in
Cameroon (Limbe Regional Hospital, General Hospital of
Yaoundé and Military Hospital of Yaoundé), and one clinic
from Malawi (Lighthouse Trust in Lilongwe). Each site
administers ART in accordance with their national guide-
lines, and each participates in the International Epidemio-
logic Databases to Evaluate AIDS (IeDEA) Consortium,
which, in Africa, consists of East, West, Central and
Southern Africa regions [22]. IeDEA was established in
2005 to harmonize diverse HIV/AIDS-related data col-
lected as part of routine clinical care in seven regions
throughout the world [23]. All patients provided written
consent for data derived from their care at the participat-
ing clinic sites to be used for purposes of research through
IeDEA. No children were involved in this study. Ethics
committees that approved this study are listed in the
Funding section of this paper.
Measurements
At the participating clinics, KS diagnosis was made dur-
ing the course of routine clinical care, either by clinical
examination alone or with biopsy confirmation. Both in-
dividuals who were diagnosed at their initial clinic visit
and during the course of their care were included. As-
certainment of death was through review of clinic charts,
clinic databases and municipal death registries, where
available. Clinics are informed of a patient’s death in a
variety of ways, including from reports from adjacent
hospital units or from family members. All of the par-
ticipating clinics had some form of a tracking program
in place to follow-up on lost patients. Demographic char-
acteristics, including age and sex, were routinely collected
by the clinics and extracted from the respective clinic
databases. CD4+ T cell counts were performed at clinical
laboratories associated with each of the clinics. The
CD4 count proximal to KS diagnosis, when available,
was defined as CD4 count closest to date of diagnosis,
within 180 days prior to KS diagnosis or up to 14 days
after.
Statistical analysis
Time zero for the analysis was date of KS diagnosis.
Patients were followed until death, and for those not
known to be dead, the last known date known to be alive
either from a clinic visit or transfer to another facility.
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via the Kaplan-Meier technique, with censoring at transfer
or last clinic visit. This approach assumes that the rate of
death among those lost to follow-up is the same as those
whose disposition is known. Loss to follow-up was defined
as absence from clinic during the 3 months prior to
database closure with no evidence of death or transfer.
Incidence of loss to follow-up was calculated using the
Aalen-Johansen estimator with death as a competing
event [24, 25]. Proportional hazards regression was
used to evaluate the independent association between
various exposures measured at the time of KS diagnosis
(age, sex and proximal CD4 count) and loss to follow-up.
For the regression analysis, missing exposure variables
were accommodated for with multiple imputation, with
ten copies, performed with the “mi impute” command in
Stata version 12.1 (Stata Corp., College Station, Texas)
[26, 27]. Standard errors were calculated using Rubin’s
rules, which account for the variability in results between
the imputed datasets [27].
Results
Across the 33 HIV clinics, we analyzed data from 1328
adults diagnosed with KS during the course of primary
care for HIV disease in all four African regions in the
IeDEA Consortium. There were 677 cases from Kenya,
172 from Uganda, 57 from Nigeria, 67 from Cameroon
and 355 from Malawi. Overall, 40 % were women, the
median age was 35 years (interquartile range (IQR): 30–41),
and the median proximal CD4 +T cell count was 159/mm3
(IQR: 59–299) at time of KS diagnosis (Table 1). Most of
the KS diagnoses (72 %) were made on clinical grounds
alone without biopsy.
Patients were followed for a median of 8.9 months
(IQR: 4.0–20) and a collective 1473 person-years in
which 191 patients died. Cumulative mortality, as estimatedTable 1 Characteristics of HIV-infected patients diagnosed with Kap
Cameroon and Malawi
AMPATH Kenya
(n = 677)
ISS Uganda
(n = 172)
UATH and NHA Nigeria
(n = 57)
Male sex, %a 60 % 60 % 49 %
Age, yearsa 35 (30–42)b 33 (28–40) 36 (30–41)
CD4+ T cell count/μlc
≤ 50 25 % 24 % 33 %
51-200 32 % 31 % 17 %
201-350 21 % 28 % 39 %
> 350 21 % 16 % 11 %
AMPATH denotes Academic Model Providing Access to Healthcare, ISS denotes Imm
Hospital, NHA denotes National Hospital of Abuja
atwo missing values for sex, four missing values for age
bmedian (interquartile range)
cCD4+ T cell count proximal to KS diagnosis, defined as closest CD4 count to date o
diagnosis. CD4 data is missing in 33 % of patients. Data presented represent observby the Kaplan-Meier technique, was 13 % at 6 months
following KS diagnosis, 18 % at 1 year, and 22 % at 2 years.
These estimates of mortality were clouded, however, by a
cumulative loss to follow-up of 23 % (95 % confidence
interval (CI): 21–26 %) at 6 months, 36 % (95 % CI: 33–
38 %) at 1 year, and 45 % (95 % CI: 42–48 %) at 2 years
(Fig. 1). This cumulative loss to follow-up takes death into
account as a competing event. At no site was there an ac-
cessible municipal death registry or any other administra-
tive source in which to search for deaths among those
deemed to be lost.
Given the high frequency of lost to follow-up, we also
explored its determinants. After adjustment for geographic
site in proportional hazards regression, age <30 years
(hazard ratio (HR) 1.41, 95 % CI: 1.11–1.79) and male
sex (HR 1.35, 95 % CI: 1.12–1.63) were independently
associated with loss to follow-up (Table 2). Those with
CD4 count ≤50 cells/mm3 also had a higher incidence
of becoming lost (HR 1.23, 95 % CI: 0.90–1.67, p = 0.19), al-
though this did not meet conventional levels of statistical
significance. When the analysis was restricted to those with
biopsy-proven KS (n = 378), the results were largely un-
changed, with the exception that CD4 count ≤50 cells/mm3
was significantly associated with loss to follow-up (HR 2.35,
95 % CI: 1.29–4.27, p < 0.01).
Discussion
When attempting to estimate survival in a large HIV pri-
mary care-based sample of patients diagnosed with KS
spanning five countries in sub-Saharan Africa, we found
that almost half were lost to follow-up by the end of
2 years. Because the fraction of those lost is so large and
the disposition of the lost is unknown, it was therefore not
possible to estimate with any certainty a fundamental
parameter in cancer epidemiology — survival — using
data from available clinical and administrative systems. Asosi’s sarcoma between 2009–2012 in Kenya, Uganda, Nigeria,
Yaounde and Limbe Cameroon
(n = 67)
Lighthouse Malawi
(n = 355)
Total
(n = 1328)
49 % 72 % 60 %
35 (30–41) 34 (30–40) 35 (30–41)
17 % 11 % 23 %
50 % 46 % 35 %
21 % 30 % 24 %
12 % 13 % 18 %
une Suppression Syndrome Clinic, UATH denotes University of Abuja Teaching
f KS diagnosis within the period 180 days prior to diagnosis to 14 days after
ed (not imputed) values only
Fig. 1 Cumulative incidence of loss to follow-up in HIV-infected patients following diagnosis with Kaposi’s sarcoma in five countries in
sub-Saharan Africa
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thod to yield an estimate of survival in the face of loss to
follow-up, it requires an assumption that those who are
lost to follow-up have the same outcomes as those who
remain under observation. Since this “non-informative
censoring” assumption is likely implausible in our context
given that a higher portion of the lost patients may in fact
have died [28], our Kaplan-Meier estimate of survival is
essentially uninterpretable.
The substantial loss to follow-up that we observed is
consistent with findings from other cancers in sub-Saharan
Africa [29, 30], as well as KS specifically. Although theTable 2 Unadjusted and adjusted proportional hazards regression e
HIV-infected patients with Kaposi’s sarcoma from Kenya, Uganda, Nig
Characteristic Unadjusted
Hazard Ratio (95 % CI) P
Age, years
≥ 40 Reference
35–39 1.00 (0.78–1.29) 0.9
30–34 1.01 (0.80–1.28) 0.9
< 30 1.30 (1.03–1.64) 0.0
Sex
Female Reference
Male 1.08 (0.91–1.30) 0.3
CD4+ T cells, count/μl
> 350 Reference
201–350 1.00 (0.74–1.35) 0.9
51–200 1.10 (0.82–1.49) 0.5
≤ 50 1.25 (0.92–1.68) 0.1
aadjusted for geographic clinic site (country), age, sex and CD4+ T cell countmethodologic approaches and metrics vary, reported loss
to follow-up for KS at 1 year or less after diagnosis in
Africa has ranged from 15 to 23 % [18, 19, 21] and was
26 % at 2 years in another report [20]. Our work, which
found an even higher incidence of lost to follow-up,
bolsters these earlier findings in several ways. First, the
IeDEA consortium is a large and diverse population,
which for this project included patients from East,
West, Central and Southern Africa, thus enhancing the
generalizability of the findings. Second, the patients
were not selected from oncology clinics, clinical trials,
registries or a tightly monitored research cohort. Instead,valuating factors associated with loss to follow-up among
eria, Cameroon and Malawi
Adjusteda
value Hazard Ratio (95 % CI) P value
Reference
6 1.06 (0.82–1.36) 0.69
3 1.09 (0.85–1.38) 0.50
3 1.41 (1.11–1.79) 0.005
Reference
8 1.35 (1.12–1.63) 0.002
Reference
9 1.03 (0.75–1.42) 0.84
2 1.14 (0.84–1.54) 0.24
5 1.23 (0.90–1.67) 0.19
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initial diagnosis in real-world community-based HIV pri-
mary care settings and their subsequent observation was
entirely without research influence. Indeed, because we
identified patients directly from HIV primary care clinics,
irrespective of whether they had a confirmatory biopsy,
our population is likely different than many registry-based
cancer populations which primarily identify KS diagnoses
from pathology laboratories. Since we do not know which
types of patients with KS in Africa obtain a biopsy diagno-
sis (e.g., they may have more severe disease, or higher so-
cioeconomic status), it is unclear if patients who receive
biopsies are representative of the larger population of all
incident KS. Therefore, if the target is to encompass all
new KS diagnoses in Africa, we believe that our estimate
of the incidence of loss to follow-up among persons with
KS is among the least biased to date.
We were unable to determine survival due to the high
loss to follow-up and the unknown disposition of those
that are lost to follow-up. In prior work from East Africa
that assessed a consecutive sample of HIV-infected
adults attending HIV clinics (including two clinics par-
ticipating in this project), we actively sought after those
who were lost by searching for them in the community
[31]. We found that three possible outcomes occur in
considerable proportions: death, previously undocumented
transfer to another facility, or alive but discontinued care
[32, 33]. Specifically, in this prior work, the cumulative in-
cidence of mortality at 1 year among those that were lost
was ultimately found to be 36 %, once the patients had
been tracked [32, 33]. Such vital status estimates, derived
from a general HIV cohort, are useful but cannot be relied
upon to accurately estimate mortality rates in selected sub-
populations such as patients with KS. Likewise, it is not
likely that nomogram approaches to correct survival in the
face of lost to follow-up that were developed for all HIV-
infected patients on ART (irrespective of KS) [34] will per-
form adequately amongst patients with KS. Work from
South Africa demonstrates that loss to follow-up is higher
in KS patients compared to other HIV-infected patients
starting on ART [21]. We speculate that this is because a
larger fraction of patients with KS die, their deaths go
unrecognized by their primary care clinics, and, hence,
they are deemed lost to follow-up. Indeed, the higher inci-
dence of loss among those with CD4 ≤ 50 cells/mm3, while
not statistically significant unless restricted to those with
biopsy-proven diagnosis, does suggest that those who were
lost became lost because of death. Therefore, the nominal
estimate of survival we observed using available data is
likely a substantial overestimate. Without ascertaining the
outcomes of those who are lost, we will never understand
true survival after a diagnosis of KS in sub-Saharan Africa.
A limitation of this work is that many of the KS diagnoses
are based on clinical suspicion only. The high frequency ofclinical diagnosis of KS has been documented by others
[35] and is largely due to the limited biopsy infrastruc-
ture in sub-Saharan Africa [36]. Work from East Africa
has shown that there are many conditions that can
clinically mimic KS [37]; it is possible that our study
population, therefore, includes patients with conditions
other than KS. Because we suspect that many more
clinical mimickers of KS have more favorable (as op-
posed to less favorable) prognosis compared to true KS,
we again believe that our nominal estimate of survival
is an overestimate of truth. In addition, due to atypically
rigorous tracking of the lost at one of our sites (Light-
house Clinic in Malawi), we may actually underestimate
the proportion of lost as it compares to a general African
clinic population. Finally, although not a threat to the in-
ternal validity of the overall findings, the sites contributed
sizably different numbers of KS cases, which is in a large
part a reflection of underlying differences in KS epi-
demiology across sub-Saharan Africa.
Conclusions
In summary, this work demonstrates on a large scale the
challenges of accurately estimating cancer survival in
sub-Saharan Africa. This issue is gaining significance as
interventions (such as chemotherapy for KS) become
more readily available, such that monitoring survival over
time is increasingly important. Until we either generally
strengthen data systems or implement cancer-specific en-
hancements to derive more accurate survival estimates
(e.g., tracking of the lost patients with cancer in the com-
munity) in the region, insights from cancer epidemiology
will be severely limited. Strengthening data systems across
this entire region may not be possible in the short term,
but sentinel regional sites could be selected for enhanced
monitoring and tracking of the lost. Additionally, the re-
cent expanding efforts in cancer registries in sub-Saharan
Africa [38–40] will need to closely address the issue of loss
to follow-up in order to truly provide added value.
Abbreviations
AIDS: acquired immune deficiency syndrome; AMPATH: Academic Model For
Prevention and Treatment of HIV; ART: antiretroviral therapy; HIV: human
immunodeficiency virus; IeDEA: International Epidemiologic Databases to
Evaluate AIDS; ISS: Immune Suppression Syndrome Clinic; KS: Kaposi’s sarcoma;
SEER: Surveillance, Epidemiology and End Results.
Competing interests
The authors declare they have no competing interests.
Authors’ contributions
EF performed the primary analysis and was responsible for manuscript
preparation. AS performed the primary analysis. MW provided data
management support and contributed to the analysis. MB oversaw
Ugandan data collection and assisted with manuscript preparation. FCA and NB
were responsible for Kenyan data collection and assisted with manuscript
preparation. EO, EJA, VK, KI, AJ and FD were responsible for Nigerian data
collection and assisted with manuscript preparation. HAY, JCD and KA were
responsible for Cameroon data collection and assisted with manuscript
preparation. DB assisted with manuscript preparation and provided
Freeman et al. BMC Cancer  (2016) 16:65 Page 6 of 7background for study design. SP, JB and ME were responsible for Malawi
data collection and assisted with manuscript preparation. CY and KWK
oversaw Kenyan and Ugandan data collection and assisted with manuscript
preparation. JM contributed to the study design, the primary analysis and
manuscript preparation. All authors have read and approved the manuscript.
Acknowledgments
We would like to acknowledge the work of many IeDEA personnel including
Beverly Musick, Donald Hoover, Michael Kanyesigye, Elyne Rotich, Clement
Adebamowo, Michael Odutala, Jesse James, Lameck Kaonga, Hannock
Tweya, Mphatso Bokosi, Salem Gugsa and Wingston Ng’ambi.
Funding
This study was funded by the National Institutes of Health (U01 AI069911,
U01 AI096299, U01 AI069919, U01 AI069924, D43 CA153717, U54 CA190153,
P30 AI027763 and T32 AR007098).
Ethics Committees that approved this study: University of California
(San Francisco), Indiana University, Partners Human Research Committee
(Harvard), Moi University, Mbarara University of Science and Technology,
University of Abuja Teaching Hospital, National Hospital of Abuja, IRB of
Albert Einstein College of Medicine/Montefiore Medical Center, Cameroon
Ethics Committee and Malawi National Health Sciences Research Committee.
Author details
1Department of Dermatology, Massachusetts General Hospital, Harvard
Medical School, Bartlett Hall 6R, 55 Fruit Street, Boston, MA 02114, USA.
2Infectious Diseases Institute, Makerere University, Kampala, Uganda.
3University of California, San Francisco, USA. 4Mbarara University of Science
and Technology, Mbarara, Uganda. 5Indiana University School of Medicine,
Indianapolis, IN, USA. 6AMPATH, Moi University, Eldoret, Kenya. 7Institute of
Human Virology, Abuja, Nigeria. 8University of Abuja Teaching Hospital,
Abuja, Nigeria. 9National Hospital of Abuja, Abuja, Nigeria. 10INSERM U897 &
ISPED, Université Bordeaux, Bordeaux, France. 11R4D International, Yaounde,
Cameroon. 12Regional Alliance for Sustainable Development, Kigali, Rwanda.
13Center for Global Health, Massachusetts General Hospital, Boston, MA, USA.
14Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY,
USA. 15Lighthouse Trust Clinic, Lilongwe, Malawi. 16University of Bern, Bern,
Switzerland. 17Indiana University Fairbanks School of Public Health,
Indianapolis, USA.
Received: 9 June 2015 Accepted: 21 January 2016
References
1. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al.
SEER cancer statistics review, 1975–2011. Bethesda: National Cancer
Institute; 2014. http://seer.cancer.gov/csr/1975_2011/.
2. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al.
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC
CancerBase No. 11. 2013. Available from: http://globocan.iarc.fr.
3. Cavalli F. Cancer in the developing world: can we avoid the disaster? Nat
Clin Pract Oncol. 2006;3(11):582–3.
4. Kulendran M, Leff DR, Kerr K, Tekkis PP, Athanasiou T, Darzi A. Global cancer
burden and sustainable health development. Lancet. 2013;381(9865):427–9.
5. Davies JN, Elmes S, Hutt MS, Mtimavalye LA, Owor R, Shaper L. Cancer in an
African Community, 1897–1956. An Analysis of the Records of Mengo
Hospital, Kampala, Uganda. 2. Br Med J. 1964;1(5379):33–41.
6. Hutt MS, Burkitt D. Geographical distribution of cancer in East Africa: a new
clinicopathological approach. Br Med J. 1965;2(5464):719–22.
7. Mbulaiteye SM, Katabira ET, Wabinga H, Parkin DM, Virgo P, Ochai R, et al.
Spectrum of cancers among HIV-infected persons in Africa: the Uganda
AIDS-Cancer Registry Match Study. Int J Cancer. 2006;118(4):985–90.
8. Wabinga HR, Parkin DM, Wabwire-Mangen F, Nambooze S. Trends in cancer
incidence in Kyadondo County, Uganda, 1960–1997. Br J Cancer.
2000;82(9):1585–92.
9. Chokunonga E, Levy LM, Bassett MT, Mauchaza BG, Thomas DB, Parkin DM.
Cancer incidence in the African population of Harare, Zimbabwe: second
results from the cancer registry 1993–1995. Int J Cancer. 2000;85(1):54–9.
10. Chokunonga E, Borok MZ, Chirenje ZM, Nyabakau AM, Parkin DM. Cancer
survival in Harare, Zimbabwe, 1993–1997. IARC Sci Publ. 2011;162:249–55.11. Cattelan AM, Calabro ML, De Rossi A, Aversa SM, Barbierato M, Trevenzoli M,
et al. Long-term clinical outcome of AIDS-related Kaposi’s sarcoma during
highly active antiretroviral therapy. Int J Oncol. 2005;27(3):779–85.
12. Bower M, Weir J, Francis N, Newsom-Davis T, Powles S, Crook T, et al. The
effect of HAART in 254 consecutive patients with AIDS-related Kaposi’s
sarcoma. AIDS. 2009;23(13):1701–6.
13. Ledergerber B, Telenti A, Egger M. Risk of HIV related Kaposi’s sarcoma and
non-Hodgkin’s lymphoma with potent antiretroviral therapy: prospective
cohort study. Swiss HIV Cohort Study. BMJ. 1999;319(7201):23–4.
14. WHO/UNAIDS/UNICEF. Global update on HIV treatment in 2013: results,
impact, and opportunities. Geneva: WHO report in partnership with UNICEF
and UNAIDS; 2013.
15. Kingham TP, Alatise OI, Vanderpuye V, Casper C, Abantanga FA, Kamara TB, et al.
Treatment of cancer in sub-Saharan Africa. Lancet Oncol. 2013;14(4):e158–67.
16. Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, et al.
Global, regional, and national incidence and mortality for HIV, tuberculosis,
and malaria during 1990–2013: a systematic analysis for the Global Burden
of Disease Study 2013. Lancet. 2014;384(9947):1005–70.
17. Hayward GS, Zong JC. Modern evolutionary history of the human KSHV
genome. Curr Top Microbiol Immunol. 2007;312:1–42.
18. Chu KM, Mahlangeni G, Swannet S, Ford NP, Boulle A, Van Cutsem G. AIDS-
associated Kaposi’s sarcoma is linked to advanced disease and high
mortality in a primary care HIV programme in South Africa. J Int AIDS Soc.
2010;13:23.
19. Makombe SD, Harries AD, Yu JK, Hochgesang M, Mhango E, Weigel R, et al.
Outcomes of patients with Kaposi’s sarcoma who start antiretroviral therapy
under routine programme conditions in Malawi. Trop Doct. 2008;38(1):5–7.
20. Nelson BC, Borok MZ, Mhlanga TO, Makadzange AT, Campbell TB. AIDS-
associated Kaposi sarcoma: outcomes after initiation of antiretroviral therapy
at a university-affiliated hospital in urban Zimbabwe. Int J Infect Dis. 2013;
17(10):e902–6.
21. Maskew M, Fox MP, van Cutsem G, Chu K, Macphail P, Boulle A, et al.
Treatment response and mortality among patients starting antiretroviral
therapy with and without Kaposi sarcoma: a cohort study. PLoS One. 2013;
8(6):e64392.
22. Egger M, Ekouevi DK, Williams C, Lyamuya RE, Mukumbi H, Braitstein P, et al.
Cohort Profile: the international epidemiological databases to evaluate AIDS
(IeDEA) in sub-Saharan Africa. Int J Epidemiol. 2012;41(5):1256–64.
23. International Epidemiologic Databases to Evaluate AIDS. Available from:
http://www.iedea.org/.
24. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD. A
note on competing risks in survival data analysis. Br J Cancer. 2004;91(7):
1229–35.
25. Schoni-Affolter F, Keiser O, Mwango A, Stringer J, Ledergerber B, Mulenga L,
et al. Estimating loss to follow-up in HIV-infected patients on antiretroviral
therapy: the effect of the competing risk of death in Zambia and Switzerland.
PLoS One. 2011;6(12):e27919.
26. Raghunathan TE, Lepkowski JM, Van Hoewyk J, Solenberger P. A multivariate
technique for multiply imputing missing values using a sequence of regression
models. Survey Methodol. 2001;27:85–95.
27. Rubin DB. Multivariate Imputation for Nonresponse in Surveys. New York:
J. Wiley & Sons; 1987.
28. Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to
follow-up in antiretroviral treatment programmes in resource-limited
settings: systematic review and meta-analysis. PLoS One. 2009;4(6):e5790.
29. Togo B, Traore F, Togo AP, Togo P, Diakite AA, Traore B, et al. Epidemiology
and prognosis of childhood cancers at Gabriel-Toure Teaching Hospital
(Bamako, Mali). Med Sante Trop. 2014;24(1):68–72.
30. Khozaim K, Orang'o E, Christoffersen-Deb A, Itsura P, Oguda J, Muliro H,
et al. Successes and challenges of establishing a cervical cancer screening
and treatment program in western Kenya. Int J Gynaecol Obstet. 2014;
124(1):12–8.
31. Geng EH, Emenyonu N, Bwana MB, Glidden DV, Martin JN. Sampling-based
approach to determining outcomes of patients lost to follow-up in
antiretroviral therapy scale-up programs in Africa. JAMA. 2008;300(5):506–7.
32. Yiannoutsos CT, An MW, Frangakis CE, Musick BS, Braitstein P, Wools-Kaloustian K,
et al. Sampling-based approaches to improve estimation of mortality among
patient dropouts: experience from a large PEPFAR-funded program in Western
Kenya. PLoS One. 2008;3(12):e3843.
33. Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB,
Yiannoutsos CT, et al. Understanding reasons for and outcomes of
patients lost to follow-up in antiretroviral therapy programs in Africa
through a sampling-based approach. J Acquir Immune Defic Syndr. 2010;
53(3):405–11.
34. Egger M, Spycher BD, Sidle J, Weigel R, Geng EH, Fox MP, et al. Correcting
mortality for loss to follow-up: a nomogram applied to antiretroviral treatment
programmes in sub-Saharan Africa. PLoS Med. 2011;8(1):e1000390.
35. Banda LT, Parkin DM, Dzamalala CP, Liomba NG. Cancer incidence in
Blantyre, Malawi 1994–1998. Trop Med Int Health. 2001;6(4):296–304.
36. Laker-Oketta M.O, Wenger M, Semeere A, Castelnuovo B, Kambugu A,
Lukande R, et al. Task Shifting and Skin Punch for the Histologic Diagnosis
of Kaposi’s Sarcoma in Sub-Saharan Africa: A Public Health Solution to a
Public Health Problem. Oncology, 2015. Epub ahead of print at
DOI: 10.1159/000375165.
37. Amerson E, Buziba N, Wabinga H, Wenger M, Bwana MB, Muyindike W, et al.
Diagnosing Kaposi’s Sarcoma (KS) in East Africa: how accurate are clinicians
and pathologists? Infectious Agents and Cancer. 2012;7(Supplement 1):6.
38. Wabinga HR, Nambooze S, Amulen PM, Okello C, Mbus L, Parkin DM. Trends
in the incidence of cancer in Kampala, Uganda 1991–2010. Int J Cancer.
2014;135(2):432–9.
39. Shimakawa Y, Bah E, Wild CP, Hall AJ. Evaluation of data quality at the
Gambia national cancer registry. Int J Cancer. 2013;132(3):658–65.
40. Jedy-Agba E, Curado MP, Ogunbiyi O, Oga E, Fabowale T, Igbinoba F, et al.
Cancer incidence in Nigeria: a report from population-based cancer
registries. Cancer Epidemiol. 2012;36(5):e271–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Freeman et al. BMC Cancer  (2016) 16:65 Page 7 of 7
